Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

Figure 1

Timeline of FDA approvals of HER2-targeted breast cancer therapies and conduct of the registHER and systHERs observational studies. BC, breast cancer; FDA, US Food and Drug Administration; HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; OS, overall survival; SystHERs, Systematic Therapies for HER2-positive Metastatic Breast Cancer Study; T-DMI, trastuzumab emtansine.

Back to article page
\